High quality MDT10 Mazdutide 10 mg/vial. 10vial/kit 99% purity Jack
5 Inquiries
2259884-03-0
Pharmaceutical
99%
Hong Kong
HUATAI
10vial
2026-11-10
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial Reference
Mazdutide is a peptide-based GLP-1 and glucagon receptor (GCGR) dual agonist. As a pharmaceutical raw material, Mazdutide is characterized by its dual receptor activity and defined peptide structure. It is suitable for API research, analytical testing, pharmaceutical development, and related manufacturing processes.
Basic Info-
Product Name:
Mazdutide
Other Name:Mazdutide;Mazdutide acetate;Mazdutide 10mg;Mazdutide 5mg 10mg;LY-3305677;Mazdutide (IBI-362;OXM-3)
CAS No.:2259884-03-0
Molecular Weight:0
EC Number:884-103-0
Color/Form:White to off-white
Categories:
Research-
Class:
Dual GLP-1R/GCGR agonist (long-acting peptide)
Status:Investigational — Phase 3 (China)
Mechanism:A long-acting dual agonist of the GLP-1 receptor (GLP-1R, Ki = 28.6 nM) and glucagon receptor (GCGR, Ki = 17.7 nM). The dual activation provides both glycemic control (via GLP-1R) and increased energy expenditure / hepatic lipolysis (via GCGR), producing weight loss beyond what GLP-1R agonism alone achieves. Administered once weekly.
EC50 (GLP1R Ki):28.6 nM
EC50 (GCGR Ki):17.7 nM
Source:GlpBio: Mazdutide (CAS 2259884-03-0); Innovent Phase Ib results (eClinicalMedicine 2022).DOI
Clinical Development:
References-
PubChem:Literature:
GlpBio: Mazdutide (CAS 2259884-03-0); eClinicalMedicine: Innovent Phase Ib results (2022); ClinicalTrials.gov: DREAMS-1 (NCT04930343)
Disclaimer:Mazdutide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials in China. This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide
-
Location:
1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province
-
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
1
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
51-100
-
Year of Establishment:
2026
-
Certifications:
COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA,COA
-
-
Inquiry History5 Inquiries
Country Product Purchase Quantity Date Posted
United States
Mazdutide
25 MG Aug 12, 2026
Nigeria
Mazdutide 10mg
20 PCS Mar 7, 2026
United States
Mazdutide
30 MG Jul 15, 2024
United Kingdom
Mazdutide
1 KG Feb 10, 2026
United States
Mazddultide cas
2 MT Nov 14, 2025 Post an enquiry for this product